HER2 Amplification, Miscellaneous Tumor, FISH, Tissue
Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
Amplification of the HER2 oncogene and overexpression of the HER2 protein have been associated with a shorter disease-free survival and shorter overall survival in some cancers. Patients whose breast or gastroesophageal cancers demonstrate HER2 amplification may be candidates for treatment with Herceptin (trastuzumab). Other tumor types may also respond to this therapy.
To guide cancer therapy, as patients with HER2 amplification may be candidates for Herceptin therapy
To confirm the presence of HER2 amplification in cases with 2+ (low-level) or 3+ (high-level) HER2 protein overexpression by immunohistochemistry
An interpretive report is provided. Results are interpreted utilizing the 2007 American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines for breast tumors.(1) Specimens with equivocal results (see Method Description) are required to have additional analysis performed on the sample per ASCO/CAP guidelines.
The degree of HER2 amplification varies in tumors. Some exhibit a high level of amplification (HER2:CEP17 ratio >4.0), whereas others exhibit low-level amplification (HER2:CEP17 ratio of 2.2-4.0). It is not currently known if patients with different levels of amplification have a similar prognosis or response to therapy.
Reports also interpret the HER2 copy number changes relative to chromosome 17 copy number (aneusomy) or potential structural changes that increase HER2 copy number.
Rare cases may not show HER2 amplification but have HER2 protein overexpression demonstrated by immunohistochemistry. The clinical significance of HER2 protein overexpression in the absence of HER2 gene amplification is unclear. However, these patients may have a worse prognosis and may be candidates for Herceptin treatment.
Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
This test is not approved by the FDA and should be used as an adjunct to existing clinical and pathologic information.
For breast or gastroesophageal tumors, order FHER2/81954 HER2 Amplification Associated with Breast Cancer, FISH, Tissue or FH2GE/60620 HER2 Amplification Associated with Gastroesophageal Cancer, FISH, Tissue.
The prognostic information provided by the HER2 status of a patient's tumor should not be interpreted in isolation because other prognostic features (eg, lymph node status, tumor size) may be of equal or greater importance in determining the patient's prognosis.
Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
An interpretative report will be provided.
Clinical References Provides recommendations for further in-depth reading of a clinical nature
Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists Guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007 Jan;131(1):18-43